Chimerix, Inc. (CMRX)

[H8ster]

What new FDA designation means for Durham's Chimerix

Durham-based biopharma Chimerix (Nasdaq: CMRX) has banked a new designation from the U.S. Food and Drug Administration.

The FDA granted Chimerix Orphan Drug Designation for its lead drug candidate brincidofovir – known as brinci – for the treatment of smallpox. Benefits of the designation include the likes of development incentives and tax credits.

While members of the Chimerix team were traveling and unavailable for interviews, a company representative said the significance of the designation is two-fold.

“First, it underscores the critical need for the research and development of lifesaving medical countermeasures in the event of a smallpox outbreak, whether naturally occurring or the result of a bioterror event,” the representative noted. “Second, it provides many benefits, including a waiver of the FDA Prescription Drug User Fee Act.”…………………...


FDA designation